Ceragon Networks Posts 2025 Results, Reiterates 2026 Guidance as Cash Position Improves

Detailed price information for Ceragon Networks Ltd (CRNT-Q) from The Globe and Mail including charting and trades.
Zacks.com on MSN

Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy?

The market expects Esperion Therapeutics (ESPR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known ...

Ceragon Networks (CRNT) Reports 2025 Revenue of $338.7M Amid 14.1% Annual Decline

Ceragon Networks Ltd. (NASDAQ:CRNT) is one of the most undervalued penny stocks to buy right now. On February 17, Ceragon Networks reported Q4 2025 revenue of $82.3 million, which was a 23% decline ...
Seeking Alpha

Ceragon Networks: Upgrading On Improved Outlook And Discounted Valuation

I have covered Ceragon Networks Ltd. (NASDAQ:CRNT) or "Ceragon" previously, so investors should view this article as an update to my earlier work on the company. Earlier this week, wireless backhaul ...

Ceragon Networks Ltd. (NASDAQ: CRNT) Q4 2025 earnings call transcript

Ceragon Networks Ltd. (NASDAQ:CRNT) Q4 2025 Earnings Call Transcript February 17, 2026 Ceragon Networks Ltd. misses on earnings expectations. Reported EPS is $0.02 EPS, expectations were $0.03.